Patents Assigned to St. Jude Children's Research Hospital
-
Patent number: 11963954Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: September 9, 2021Date of Patent: April 23, 2024Assignees: Memorial Sloan Kettering Cancer Center, St. Jude Children's Research HospitalInventors: Jaeki Min, Daniel C. Scott, Deepak Bhasin, Brenda A. Schulman, Bhuvanesh Singh, Jared T. Hammill, R. Kiplin Guy
-
Patent number: 11946053Abstract: The invention provides methods for overcoming glucocorticoid resistance of cancers by inhibition of CASP1. Also disclosed are diagnostic methods for determining glucocorticoid resistance potential by measuring expression level or promoter methylation status of CASP1 gene and/or NLRP3 gene.Type: GrantFiled: October 2, 2019Date of Patent: April 2, 2024Assignee: St. Jude Children's Research Hospital, Inc.Inventors: Steven W. Paugh, William E. Evans, Erik Bonten
-
Patent number: 11905553Abstract: Provided herein are compositions and methods for accurate and scalable Primary Template-Directed Amplification (PTA) nucleic acid amplification and sequencing methods, and their applications for research, diagnostics, and treatment.Type: GrantFiled: January 28, 2019Date of Patent: February 20, 2024Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.Inventors: Charles Gawad, John Easton, Veronica Gonzalez-Pena
-
Patent number: 11891378Abstract: The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: December 26, 2018Date of Patent: February 6, 2024Assignees: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., COA THERAPEUTICS, INC.Inventors: Richard E. Lee, Rajendra P. Tangallapally, Charles O. Rock, Suzanne Jackowski, Anne V. Edwards, Mi Kyung Yun, Chitra Subramanian, Robert Zamboni, T. Jagadeeswar Reddy
-
Patent number: 11883491Abstract: Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.Type: GrantFiled: April 30, 2018Date of Patent: January 30, 2024Assignee: St. Jude Children's Research Hospital, Inc.Inventors: Jian Zuo, Fei Zheng, Tetsuji Yamashita, Zoe Kellard, Tal Teitz, Jaeki Min, Taosheng Chen
-
Patent number: 11873512Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.Type: GrantFiled: October 9, 2020Date of Patent: January 16, 2024Assignees: St. Jude Children's Research Hospital, Inc., National University of SingaporeInventors: Dario Campana, Yu-Hsiang Chang
-
Publication number: 20230340040Abstract: The present disclosure provides chimeric MyD88 receptors. Also provided are polynucleotides encoding the chimeric MyD88 receptors, vectors comprising the polynucleotides encoding the chimeric MyD88 receptors, and cell compositions comprising the chimeric MyD88 receptors, polynucleotides and/or vectors. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a disease in a subject are also provided.Type: ApplicationFiled: April 14, 2021Publication date: October 26, 2023Applicant: St. Jude Children's Research Hospital, Inc.Inventors: Stephen GOTTSCHALK, Brooke PRINZING
-
Publication number: 20230340067Abstract: The present invention provides methods of genetically modifying an immune cell such that the immune cell expresses a transgene in an activation dependent manner. The application also provides genetically modified immune cells prepared using such methods, and the uses of the genetically modified immune cells in immunotherapy (e.g., adoptive cell therapy) for treatment of a disease such as cancer, autoimmune disease or infectious disease.Type: ApplicationFiled: June 25, 2021Publication date: October 26, 2023Applicant: St. Jude Children's Research Hospital, Inc.Inventors: Stephen GOTTSCHALK, Giedre KRENCIUTE, Zelda ODE
-
Patent number: 11787768Abstract: In one aspect, compounds and compositions that modulate a bromodomain and methods of making and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with inhibition of a bromodomain such as, for example, cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: March 4, 2021Date of Patent: October 17, 2023Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: R. Kip Guy, P Jake Slavish, William Robert Shadrick, Brandon M. Young, Vincent A. Boyd, Nagakumar Bharatham, Jeanine E. Price, Anang Shelat
-
Publication number: 20230312671Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising an extracellular target-binding domain comprising at least one glucose-regulated-protein 78 (GRP78)-binding moiety. The present invention further provides polynucleotides and recombinant vectors encoding such CARs. The present invention further provides isolated host cells and methods for preparing isolated host cells expressing the CARs. The present invention further provides pharmaceutical compositions comprising the host cells and methods for treating a tumor using the pharmaceutical compositions.Type: ApplicationFiled: April 23, 2021Publication date: October 5, 2023Applicant: St. Jude Children's Research Hospital, Inc.Inventors: Mireya Paulina VELASQUEZ, Stephen GOTTSCHALK, Nikhil HEBBAR, Rebecca EPPERLY, Abishek VAIDYA
-
Patent number: 11744896Abstract: Provided are CDK2-PROTAC compounds and pharmaceutical compositions thereof that can be used for specific degradation of the cyclin-dependent kinase 2 (CDK2) protein, for treatment of cancers and other CDK2 related diseases as well as for prevention and treatment of hearing loss.Type: GrantFiled: September 28, 2021Date of Patent: September 5, 2023Assignees: CREIGHTON UNIVERSITY, ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (TENNESSEE NOT FOR PROFIT CORPORATION)Inventors: Jian Zuo, Santanu Hati, Marisa Laura Zallocchi, Robert Hazlitt, Jaeki Min
-
Patent number: 11707449Abstract: Methods and formulations are provided for treating spinobulbar muscular atrophy in a subject in need thereof. By administering a therapeutically effective amount of a selective androgen receptor modulator or a small molecule such as 1-[2-(4-methylphenoxy)ethyl]-2-[(2-phenoxyethyl)sulfanyl]-1H-benzimidazole or a derivative, prodrug, or pharmaceutically acceptable salt thereof, one or more symptoms of spinobulbar muscular atrophy can be ameliorated. The effective amount can be effective to prevent or delay loss of body weight, a loss of mobility, and/or a loss of physical strength in the subject; to prevent or delay neurogenic atrophy and/or to prevent a loss of spinal cord motor neurons in the subject; to restore the frequency of type I myofibers to normal levels for a healthy subject; and/or to reverse testicular atrophy in the subject.Type: GrantFiled: October 26, 2018Date of Patent: July 25, 2023Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.Inventor: Joseph Paul Taylor
-
Patent number: 11709164Abstract: Methods for detecting the presence of proteins in a subject are described. The proteins detected can be indicative of acute myeloid leukemia (AML). The proteins can be particularly useful for monitoring minimal residual disease (MRD) in AML.Type: GrantFiled: October 26, 2018Date of Patent: July 25, 2023Assignees: National University of Singapore, St. Jude Children's Research Hospital, Inc.Inventors: Dario Campana, Elaine Coustan-Smith
-
Publication number: 20230201208Abstract: Provided herein are compositions containing a therapeutically effective amount of at least one ADAMTS4 inhibitor, such as a specific ADAMTS4 inhibitor, and a therapeutically effective amount of at least one antibiotic, and the use of such compositions in treating an infection in a subject in need thereof. Also disclosed herein are methods for treating an infection in a subject in need thereof, by administering to the subject a therapeutically effective amount of at least one ADAMTS4 inhibitor, such as a specific ADAMTS4 inhibitor, and a therapeutically effective amount of at least one antibiotic.Type: ApplicationFiled: April 19, 2021Publication date: June 29, 2023Applicant: St. Jude Children's Research HospitalInventors: Paul Thomas, David F. Boyd
-
Patent number: 11684664Abstract: Compositions nod methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections. Compositions provided herein comprise a variety immunogenic fusion proteins, wherein at least one polypeptide component of a given fusion protein comprises a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing die various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and/or acytolysoid polypeptide, or an active variant or fragment thereof.Type: GrantFiled: April 16, 2020Date of Patent: June 27, 2023Assignee: St. Jude Children's Research HospitalInventors: Elaine Tuomanen, Elizabeth R. Mann
-
Patent number: 11673937Abstract: The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.Type: GrantFiled: November 3, 2017Date of Patent: June 13, 2023Assignee: St. Jude Children's Research Hospital, Inc.Inventors: Dario Campana, Chihaya Imai
-
Publication number: 20230174653Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising an extracellular target-binding domain comprising a B7-H3 binding moiety. The present invention further provides polynucleotides and recombinant vectors encoding such CARs. The present invention further provides isolated host cells and methods for preparing isolated host cells expressing the CARs. The present invention further provides pharmaceutical compositions comprising the isolated host cells and methods for treating a tumor using the pharmaceutical compositions.Type: ApplicationFiled: April 6, 2021Publication date: June 8, 2023Applicant: St. Jude Children's Research Hospital, Inc.Inventors: Stephen GOTTSCHALK, Christopher DERENZO, Phuong NGUYEN
-
Patent number: 11643682Abstract: Provided herein are compositions and methods for accurate and scalable Primary Template-Directed Amplification (PTA) nucleic acid amplification and sequencing methods, and their applications for research, diagnostics, and treatment.Type: GrantFiled: August 31, 2022Date of Patent: May 9, 2023Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.Inventors: Charles Gawad, John Easton, Veronica Gonzalez-Pena
-
Publication number: 20230128609Abstract: Compositions and methods are provided for suppressing tumors by modulating the LAP pathway. Targeting components of the LAP pathway for specific drug design can be used as n immunotherapy strategy that modulates the tumor microenvironment. It is well established that infiltrating monocytes and macrophages play a pivotal role in shaping an immunosuppressive tumor microenvironment. By modulating LAP in the innate immune cells, the function of effector T cells can be manipulated toward an effective, cytotoxic immune response that can eliminate tumor cells. Thus, methods are provided for reducing the size or number of tumor cells and for treating cancer or other cell proliferative disorders. Further provided are methods for increasing the Th1 response or increasing IFN? and/or TNF? expression in the tumor microenvironment by administering a LAP inhibitor.Type: ApplicationFiled: August 15, 2022Publication date: April 27, 2023Applicant: St. Jude Children's Research HospitalInventors: Douglas R. Green, Larissa Dias da Cunha
-
Publication number: 20230088509Abstract: This disclosure relates to compositions and methods of diagnosing neurodegenerative disease by analyzing protein expression profiles in a subject.Type: ApplicationFiled: May 19, 2021Publication date: March 23, 2023Applicant: St. Jude Children's Research HospitalInventors: Junmin Peng, Hong Wang, Kaushik Kumar Dey